• KOL
    • Tinea Pedis
    • Hiroyuki Tanuma
    • Hiroyuki Tanuma: Influence Statistics

      Hiroyuki Tanuma

      Hiroyuki Tanuma

      Department of Dermatology, Nippon Medical School | Tanuma Dermatology Clinic, Saitama, Japan | Dermatology, School of Medicine, Kitasato University, | Tanuma Dermatological ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Hiroyuki Tanuma:Expert Impact

      Concepts for whichHiroyuki Tanumahas direct influence:Tinea pedis,Visceral mycoses,Horny layer,Tinea unguium,Oral terbinafine,Stratum corneum,Kerion celsi,Type tinea.

      Hiroyuki Tanuma:KOL impact

      Concepts related to the work of other authors for whichfor which Hiroyuki Tanuma has influence:Fungal infections,Tinea unguium,Visceral mycoses,Aspergillus fumigatus,Oral terbinafine,Autopsy cases,Cutaneous sporotrichosis.

      KOL Resume for Hiroyuki Tanuma

      Year
      2011

      Department of Dermatology, Nippon Medical School

      2008

      Tanuma Dermatology Clinic, Saitama, Japan

      2003

      Dermatology, School of Medicine, Kitasato University,

      2001

      Tanuma Dermatological Clinic, Kawaguchi, Saitama Japan,

      Department of Dermatology,

      2000

      Department of Dermatology, Kitasato University School of Medicine, Kitasato,

      1999

      Department of Dermatology, Kitasato University School of Medicine, Kanagawa, Japan.

      1998

      Department of Dermatology, Kitasato University School of Medicine, Sagamihara, Kanagawa

      1997

      Department of Dermatology, Kitasato University School of Medicine, Kitasato, Sagamihara, Japan

      1995

      Department of Dermatology, Kitasato University, Sagmihara‐shi, Kanagawa, Japan

      Sample of concepts for which Hiroyuki Tanuma is among the top experts in the world.
      Concept World rank
      hyperkeratotic tinea pedis #2

      Prominent publications by Hiroyuki Tanuma

      KOL-Index: 12678

      To study the relationship between the changes in visceral mycoses rates and recently advanced medical care in hematological settings, data on visceral mycosis cases with leukemia and myelodysplastic syndrome (MDS) that had been reported in the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997 were analyzed. The frequency rate of visceral mycoses with leukemia and MDS was 27.9% (435/1557) in 1989, 23.0% (319/1388) in 1993 and 22.3% (246/1105) in 1997. In comparing ...

      Known for Autopsy Cases | Leukemia Mds | Rate Mycoses | Data Annual | Myelodysplastic Syndrome
      KOL-Index: 11127

      To study the changes of visceral mycoses in autopsy cases, data on visceral mycosis cases with leukemia and myelodysplastic syndrome (MDS) reported in the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993, 1997 and 2001 were analyzed. The frequency rate of visceral mycoses with leukemia and MDS was 27.9% (435/1,557) in 1989, 23.0% (319/1,388) in 1993, 22.3% (246/1,105) in 1997 and 25.1% (260/ 1,037) in 2001, which was clearly higher than the rate of cases without leukemia ...

      Known for Visceral Mycoses | Leukemia Mds | Candida Aspergillus | Autopsy Cases | Myelodysplastic Syndrome
      KOL-Index: 9913

      The data on visceral mycoses reported in the " Annual of Pathological Autopsy Cases in Japan " were analyzed epidemiologically every four years from 1989 to 2005, and in 2007. The frequency rates of visceral mycoses dropped sharply between 1989 (4.5%) and 1994 (3.2%), but by 2001 had risen again and have remained (4.4-4.6%) generally stable since then. The predominant causative agents were Candida and Aspergillus. Although the rate of candidosis showed a gradual decrease, the rate of ...

      Known for Visceral Mycoses | Autopsy Cases | Japan Data | Aspergillus Candida | Bacterial Infections
      KOL-Index: 6390

      In this study, in addition to studying the efficacy and safety of the once-daily administration of 100-mg capsules of fluconazole over an 8-week administration period with six patients with hyperkeratotic-type tinea pedis, we also measured the serum and horny layer concentrations of fluconazole to study the mobility into the horny layer in diseased areas of the sole skin. The final overall efficacy and overall safety were both 100% (six out of six), and no side-effects, including ...

      Known for Tinea Pedis | Hyperkeratotic Type | Horny Layer | Efficacy Safety | Stratum Corneum
      KOL-Index: 5688

      A clinical trial of once-daily administration of a 125-mg tablet of terbinafine, an oral antimycotic agent, was performed on patients with tinea unguium to evaluate its efficacy, safety, possible side-effects and its incorporation into nails and hair. Thirty-four patients were recruited into the study. For the statistical analysis, one of these patients was used only for the safety rating. Accordingly, 33 patients were used for the efficacy rating, and all 34 patients were employed for ...

      Known for Tinea Unguium | Oral Terbinafine | Pharmacokinetic Study | Clinical Trial | Laboratory Test Values
      KOL-Index: 5612

      A clinical study was carried out in 19 patients with onychomycosis in whom itraconazole was orally administered in a single daily dose of 100 mg. A follow-up period was instituted subsequent to the administration period to that the course of the nail lesions could be monitored. The concentrations of the drug in the plasma and in the nails were also determined. In patients in whom itraconazole was administered for 12-16 weeks, the decrease in the turbidity and thickening of the nails was ...

      Known for Oral Itraconazole | 19 Patients | Aged Onychomycosis | Antifungal Agents | Completion Administration
      KOL-Index: 4995

      Moccasin-type tinea pedis (MTTP) is characterized by hyperkeratosis of the sole, which is generally refractory to treatment. As topical application of an antimycotic agent alone often fails to control this disease, oral griseofulvin is commonly used. We attempted the treatment of MTTP with topical bifonazole (Mycospor Solution) alone (group I) or in combination with 10% urea ointment (Urepearl) (group II) and compared the clinical benefit of these two therapies. The clinical improvement ...

      Known for Tinea Pedis | Treatment Mttp | Combination Therapy | 10 Urea Ointment | 4 Weeks
      KOL-Index: 4274

      In the present study, the authors administered 100 mg itraconazole (ITCZ) twice daily for a period of 1 week to six patients with hyperkeratotic type tinea pedis, and examined its efficacy, safety profile, and usefulness. ITCZ concentration in stratum corneum was also measured to examine the mobility of the drug into the affected site of planta pedis. ITCZ concentration in the stratum corneum of the affected part was first detected at 1 week after the completion of administration, ...

      Known for Tinea Pedis | Stratum Corneum | 2 Weeks | 1 Week | Administration Oral
      KOL-Index: 4259

      Moccasin-type tinea pedis(MTTP) is a hardly curable superficial dermatomycosis primarily characterized by hyperkeratosis of the sole. In this study, we compared the usefulness of combination therapy of bifonazole (Mycospor cream) + 10% urea ointment (Urepearl) (overlapping application group = group I) with occlusive dressing therapy with the same agents (group II) in the treatment of MTTP, and obtained the following results. (1) The clinical improvement rate (percentage of "marked ...

      Known for Combination Therapy | Tinea Pedis | Urea Ointment | 4 Weeks | Publication Administration
      KOL-Index: 3956

      Hyperkeratotic type tinea pedis is a refractory type of superficial dermatomycosis. Treatment for hyperkeratotic type tinea pedis is mainly with oral antimycotics, such as griseofulvin, and healing is generally considered to be difficult with only topical antimycotics. In this randomized comparative study, the usefulness of a topical application of 1% lanoconazole cream (Astat) monotherapy (group I) was compared with that of combination therapy with 1% lanoconazole cream and 10% urea ...

      Known for Tinea Pedis | Urea Ointment | Combination Therapy | Hyperkeratotic Type | 4 Weeks
      KOL-Index: 3836

      Forty-five patients were divided into two groups: group I, 23 patients, treated with butenafine hydrochloride (Mentax) cream alone, and group II, 22 patients, treated with butenafine hydrochloride and 20% urea ointment (Keratinamin) to evaluate the usefulness of the treatments. We also measured the transfer of these drugs to the horny layer in some patients. The clinical improvement rate of dermatological symptoms (marked improvement + improvement) was 91.3% in group I, 100% in group II, ...

      Known for Butenafine Hydrochloride | Tinea Pedis | Urea Ointment | Antifungal Agents | Hyperkeratotic Type
      KOL-Index: 3805

      The usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer were evaluated. Of the 36 patients enrolled in the study, 35 were retained for analysis and one was excluded due to inappropriate drug application. Hyperkeratotic-type tinea pedis was classified into three types: true hyperkeratotic-type, partial hyperkeratotic-type, and quasi-hyperkeratotic type. The overall clinical improvement rate was 95.5% (100% for true-, ...

      Known for Type Tinea | Horny Layer | Publication Administration | Pedis Treatment | Skin Terbinafine
      KOL-Index: 3496

      A 75-year-old non-working male living in Sagamihara, Kanagawa Prefecture, had erythematous plaques with scales associated with follicular pustules in the head area extending from the occipital to right temporal regions about 1 month prior to his initial visit, when hair loss increased. The diagnosis was kerion Celsi. Trichophyton rubrum was isolated from scales and tissues taken from lesions in the head. Histopathological examinations showed irregular epidermal thickening with dense cell ...

      Known for Kerion Celsi | Tinea Capitis | Trichophyton Rubrum | Antifungal Agents | Hair Follicles
      KOL-Index: 3190

      The number of patients with tinea unguium accounts for 0.5% to 2% of the total number of outpatients in Japan. The diagnosis of tinea unguium can be relatively easily made on the basis of clinical symptoms and direct microscopic findings. However onychomycosis due to fungi other than dermatophytes should always be suspected if no dermatophytes are cultured despite positive findings in direct microscopy. In such cases, it is necessary to repeat cultures and conduct histopathological ...

      Known for Tinea Unguium | Oral Administration | Griseofulvin Treatment | Antifungal Agents | Humans Itraconazole
      KOL-Index: 2957

      A 38-year-old male with history of trauma in the left gluteal region 20 years ago presented with a dark red skin eruption at the traumatized area. It gradually grew to form an erythematous plaque with a well-defined border. Clinical findings and mycological cultures resulted in the diagnosis of chromoblastomycosis due to Fonsecaea pedrosoi. After initial administration of 5-fluorocytosine and local heat an almost complete cure was achieved with terbinafine combined with local heat ...

      Known for Chromoblastomycosis Female Humans | Fonsecaea Pedrosoi | Antifungal Agents | Local Heat | Clinical Findings

      Key People For Tinea Pedis

      Top KOLs in the world
      #1
      Boni Elizabeth Elewski
      tinea capitis nail psoriasis seborrheic dermatitis
      #2
      Aditya Kumar Gupta
      tinea capitis seborrheic dermatitis antifungal agents
      #3
      Richard C Summerbell
      tinea capitis malassezia species trichophyton rubrum
      #4
      Nardo Zaias
      tinea pedis oral terbinafine nail bed
      #5
      Roderick James Hay
      global burden skin disease tinea capitis
      #6
      James Joseph Leyden
      acne vulgaris benzoyl peroxide staphylococcus aureus

      Department of Dermatology, Nippon Medical School | Tanuma Dermatology Clinic, Saitama, Japan | Dermatology, School of Medicine, Kitasato University, | Tanuma Dermatological Clinic, Kawaguchi, Saitama Japan, | Department of Dermatology,

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.